Pilot Study of Extended-release Exenatide to Improve Glucose Control and Reduce Systemic Inflammation in Diabetic, HIV-infected Adults on Antiretroviral Therapy
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Exenatide (Primary)
- Indications Diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 20 Jan 2017 Status changed to discontinued due to loss of funding.
- 20 Feb 2013 New trial record